Drug Trial Radar · NCT01543763
Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Jun 25, 2012
Primary completion
Jan 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Pamela MunsterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Pharmacyclics LLC.; Novartis; Xynomic Pharmaceuticals, Inc.; GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease
- First posted
- Mar 5, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a open-label non-randomized, dose escalation and expansion Phase Ia/Ib study to determine the safety, tolerability and maximum tolerated dose (MTD) of pazopanib in combination with PCI-24781 in patients with advanced solid tumors.
Conditions
- Metastatic Solid Tumors
Interventions
PZP115891, PCI-24781Drug
PCI-24781: oral, 30 to 75 mg/m2 b.i.d. Cycle 1, Days -7 to -4 and Cycle 1 and ongoing - Days 1-5, 8-12, 15-19 PZP115891: oral, 400 - 800 mg qd 28 days per cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity (DLT)Time frame: up to 4 weeks
- Maximum Tolerated Dose (MTD)Time frame: up to 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of California, San Francisco
San Francisco, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.